

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method of increasing insulin sensitivity in a mammalian patient ~~who has with~~ Type II diabetes ~~or is at risk of developing Type II diabetes~~, comprising administering to the patient an effective amount of a therapeutic nitric oxide donor compound for increasing insulin sensitivity, wherein said nitric oxide donor compound is selected from the group consisting of: 3-morpholinosydnonimine (SIN-1), sodium nitrite, nitroprusside, and S-nitroso-N-acetyl-D, L-penicillamine (SNAP).
2. (Previously Presented) The method according to claim 1, wherein said administering step comprises orally administering the compound.
3. (Previously Presented) The method according to claim 1, wherein said administering step comprises injecting the compound.
- 4-18. (Cancelled)
19. (Previously Presented) The method according to claim 1, wherein said insulin sensitivity is hepatic sensitizing substance (HISS) dependent insulin sensitivity.
20. (Cancelled)
21. (Previously Presented) A method of increasing insulin sensitivity, comprising
  - a) administering a unit dosage injectable formulation comprising an effective amount of a nitric oxide donor or nitric oxide agonist for increasing insulin sensitivity; and

b) subsequently administering an oral dosage formulation comprising an effective amount of a nitric oxide donor or nitric oxide agonist for maintaining insulin sensitivity.

22. (Previously Presented) The method of claim 21, wherein the nitric oxide donor or nitric oxide agonist of (a) or (b) is selected from the group consisting of 3-morpholinomethyl-5-nitro-1H-imidazole-4-carboxylate (SIN-1), sodium nitrite, nitroprusside, and S-nitroso-N-acetyl-D,L-pencillamine (SNAP).

23. (Previously Presented) The method of claim 21, wherein the nitric oxide donor or nitric oxide agonist of (a) or (b) is a pharmaceutically acceptable salt.

24. (Previously Presented) The method of claim 21, wherein the oral dosage formulation is a tablet or capsule.

25. (Currently Amended) The method of claim 21, wherein the ~~kit~~ method comprises administering more than one tablet or capsule.